Why in news?
Four prospective candidates to lead the World Health Organization (WHO) discussed the agency's future in Berlin on 11 October 2026. Their panel formed part of the World Health Summit, held from 11 to 13 October. Its theme was “From Crisis to Resilience: Innovating for Health”. Health Policy Watch reported differences over prevention, financing, institutional reform and patient outcomes. These questions matter because international health cooperation needs credible science, resources and institutions that can work with national governments. The discussion offered an opportunity to examine competing priorities before the leadership appointment expected in May 2027. It was a public forum, not WHO's nomination or election meeting. The formal decision remains with the organisation's governing bodies under a separate, published process.
A conference is not a governing assembly
The World Health Summit brings together science, government, civil society and the private sector to discuss health priorities. Its Berlin event has been held since the initiative's establishment in 2009. That broad composition gives participants opportunities to exchange evidence and proposals. It does not give conference participants the voting powers of governments within WHO.
The World Health Assembly is a different institution. Delegations from WHO member states meet there to determine policy, appoint the Director-General and oversee financial matters and the programme budget. It normally meets in Geneva, Switzerland. Keeping the two names separate is essential: a statement made at the Berlin summit is not automatically a decision adopted by the Health Assembly.
What the public discussion revealed
The reported participants were Hanan Al-Kuwari, María Neira, Budi Gunadi Sadikin and Gevorg Tamamyan. The organiser's advance announcement had listed five prospective participants, but the account of the actual session reported four speakers. An advertised panel and an attended panel are different records. Their participation also should not be confused with WHO's eventual list of formally nominated candidates.
Health Policy Watch described Al-Kuwari's emphasis on reviewing institutional functions and Neira's focus on preventing disease through healthier environments. Sadikin stressed scientific guidance and financing, while Tamamyan emphasised patients' outcomes and practical help. These are reported campaign positions, not policies already adopted by WHO. They provide questions against which later proposals can be examined, rather than evidence that the proposed changes have been delivered.
Why financing shapes what an institution can do
WHO's financing combines assessed contributions and voluntary contributions. Assessed contributions are membership dues paid by governments under the agreed arrangements. Voluntary funding comes from states and other partners, with different conditions attached. Some contributions are flexible; others are assigned to particular activities. A large total does not therefore mean every dollar can be redirected to whichever need arises next.
This distinction explains the importance of predictable and flexible finance in a reform debate. An institution needs resources for the work its governing bodies approve, including needs that may attract less donor attention. At the same time, contributors seek accountability for the use of their money. WHO's funding explanation identifies a member-state goal of increasing assessed contributions to half of the base budget by 2030. That is a financing objective, not a claim that the share has already been reached.
The formal appointment process
WHO invited member states to propose candidates on 24 April 2026, with submissions due by 24 September. Its published timetable said names and proposals would be made public at the beginning of November, after the year's final regional committee session. Publicly declared candidacies and appearances before that point do not replace the Secretariat's formal publication or the subsequent screening process.
The Executive Board conducts initial screening and develops a shortlist. At its January 2027 session, it is to nominate up to three candidates for consideration by the World Health Assembly. The Assembly is then expected to appoint the Director-General in May 2027. A conference audience does not perform either of these institutional steps.
The Director-General is WHO's chief technical and administrative officer. The appointment is for five years, with reappointment permitted once. Tedros Adhanom Ghebreyesus began his second term on 16 August 2022, and WHO records its conclusion on 15 August 2027. The next term is scheduled to begin on 16 August 2027. The timetable therefore concerns a future succession, not a leadership change completed at the October summit.
Cooperation involves more than choosing a leader
The summit's wider programme concerns how health institutions work together under pressure. One concrete example came in Tedros's opening-night address: the WHO Hub for Pandemic and Epidemic Intelligence in Berlin. The hub opened in September 2021 to support collaboration around detecting and understanding health threats. The mechanism connects information and expertise across organisations, rather than relying on one country to notice every emerging danger alone.
The address also introduced a strategy aiming to help every country detect and understand a new health threat within 24 hours. That is an ambition for future capability, not a finding that the world already meets a universal one-day standard. Early information must still lead to appropriate interpretation and action. The example shows why technical networks and national capacity matter alongside leadership and funding.
From broad agreement to workable reform
Many people can agree that cooperation should be efficient, evidence-based and fair. The harder questions concern how responsibilities are allocated, which activities receive money and how results are assessed. A proposal to remove duplication needs to identify the duplicated work and the institution still responsible for performing it. Otherwise, reducing an organisational overlap could simply leave an essential task unattended.
The leadership discussion is therefore useful when it makes such choices open to scrutiny. Candidate statements can be compared with the formal mandate, budget constraints and country needs. Their value lies in the clarity of the choices and the feasibility of follow-through, not simply the confidence of a public presentation.
Conclusion
The Berlin panel brought different ideas about WHO's future into a public discussion before the 2027 appointment. It did not nominate finalists, elect a Director-General or enact the speakers' proposals. The summit's wider message is that health resilience depends on scientific cooperation, usable information and sustainable institutions. The next substantive steps are the formal candidate process and proposals detailed enough to show how those institutions would work better.